156 related articles for article (PubMed ID: 32629400)
1. Factors Associated with Prescribing Oral Disease Modifying Agents in Multiple Sclerosis: a Real-world Analysis of Electronic Medical Records.
Earla JR; Hutton GJ; Thornton JD; Aparasu RR
Mult Scler Relat Disord; 2020 Oct; 45():102334. PubMed ID: 32629400
[TBL] [Abstract][Full Text] [Related]
2. Prescribing of disease modifying agents in older adults with multiple sclerosis.
Talwar A; Earla JR; Hutton GJ; Aparasu RR
Mult Scler Relat Disord; 2022 Jan; 57():103308. PubMed ID: 35158421
[TBL] [Abstract][Full Text] [Related]
3. FACTORS ASSOCIATED WITH SWITCHING FROM INJECTABLE TO ORAL DISEASE MODIFYING AGENTS AMONG PATIENTS WITH MULTIPLE SCLEROSIS.
Li J; Chikermane SG; Earla JR; Hutton GJ; Aparasu RR
Mult Scler Relat Disord; 2022 Apr; 60():103703. PubMed ID: 35278846
[TBL] [Abstract][Full Text] [Related]
4. Factors associated with oral fingolimod use over injectable disease- modifying agent use in multiple sclerosis.
Earla JR; Hutton GJ; Thornton JD; Chen H; Johnson ML; Aparasu RR
Explor Res Clin Soc Pharm; 2021 Jun; 2():100021. PubMed ID: 35481133
[TBL] [Abstract][Full Text] [Related]
5. Comparative Adherence Trajectories of Oral Fingolimod and Injectable Disease Modifying Agents in Multiple Sclerosis.
Earla JR; Hutton GJ; Thornton JD; Chen H; Johnson ML; Aparasu RR
Patient Prefer Adherence; 2020; 14():2187-2199. PubMed ID: 33177813
[TBL] [Abstract][Full Text] [Related]
6. Use of disease modifying agents in patients with multiple sclerosis: Analysis of ten years of national data.
Earla JR; Paranjpe R; Kachru N; Hutton GJ; Aparasu RR
Res Social Adm Pharm; 2020 Dec; 16(12):1670-1676. PubMed ID: 32171597
[TBL] [Abstract][Full Text] [Related]
7. Comparative treatment effectiveness of oral fingolimod and conventional injectable disease-modifying agents in multiple sclerosis.
Earla JR; Hutton GJ; Thornton DJ; Chen H; Johnson ML; Aparasu RR
Pharmacotherapy; 2021 May; 41(5):440-450. PubMed ID: 33641232
[TBL] [Abstract][Full Text] [Related]
8. Association of oral disease-modifying agents and their adherence trajectories with annual relapses in multiple sclerosis.
Earla JR; Li J; Hutton GJ; Bentley JP; Aparasu RR
Mult Scler Relat Disord; 2024 May; 85():105539. PubMed ID: 38574721
[TBL] [Abstract][Full Text] [Related]
9. Comparative adherence trajectories of oral disease-modifying agents in multiple sclerosis.
Earla JR; Li J; Hutton GJ; Johnson ML; Aparasu RR
Pharmacotherapy; 2023 Jun; 43(6):473-484. PubMed ID: 37157135
[TBL] [Abstract][Full Text] [Related]
10. Assessing treatment switch among patients with multiple sclerosis: A machine learning approach.
Li J; Huang Y; Hutton GJ; Aparasu RR
Explor Res Clin Soc Pharm; 2023 Sep; 11():100307. PubMed ID: 37554927
[TBL] [Abstract][Full Text] [Related]
11. The association of timing of disease-modifying drug initiation and relapse in patients with multiple sclerosis using electronic health records.
Corvino FA; Oliveri D; Phillips AL
Curr Med Res Opin; 2017 Jun; 33(6):1127-1132. PubMed ID: 28318337
[TBL] [Abstract][Full Text] [Related]
12. The use of disease-modifying agents among multiple sclerosis patients enrolled in medicare from 1995 to 2002 and the impact of medicare part D: analysis of claims data from the medicare current beneficiary survey.
Lundy J; Craig BM
Clin Ther; 2006 Jan; 28(1):140-5. PubMed ID: 16490588
[TBL] [Abstract][Full Text] [Related]
13. Baseline characteristic differences between patients prescribed sitagliptin vs. other oral antihyperglycemic agents: analysis of a US electronic medical record database.
Zhang Q; Rajagopalan S; Mavros P; Engel SS; Davies MJ; Yin D; Radican L
Curr Med Res Opin; 2010 Jul; 26(7):1697-703. PubMed ID: 20465367
[TBL] [Abstract][Full Text] [Related]
14. Disease-modifying agents in the Sonya Slifka Longitudinal Multiple Sclerosis Study.
Minden S; Hoaglin D; Jureidini S; Hadden L; Frankel D; Komatsuzaki Y; Outley J
Mult Scler; 2008 Jun; 14(5):640-55. PubMed ID: 18566028
[TBL] [Abstract][Full Text] [Related]
15. A cohort study examining headaches among veterans of Iraq and Afghanistan wars: Associations with traumatic brain injury, PTSD, and depression.
Jaramillo CA; Eapen BC; McGeary CA; McGeary DD; Robinson J; Amuan M; Pugh MJ
Headache; 2016 Mar; 56(3):528-39. PubMed ID: 26688427
[TBL] [Abstract][Full Text] [Related]
16. Intracerebral Hemorrhage in Multiple Sclerosis: A Retrospective Cohort Study.
Zulfiqar M; Qeadan F; Ikram A; Farooqui M; Richardson SP; Calder CS; Quadri SA; Mathur P; Ford C; O Gutierrez S; Liera E; Snow H; N Gonzalez J; Zafar A
J Stroke Cerebrovasc Dis; 2019 Feb; 28(2):267-275. PubMed ID: 30385221
[TBL] [Abstract][Full Text] [Related]
17. Sociocultural and Demographic Risk Factors for the Development of Multiple Sclerosis in Kuwait: A Case - Control Study.
Al-Shammri SN; Hanna MG; Chattopadhyay A; Akanji AO
PLoS One; 2015; 10(7):e0132106. PubMed ID: 26132203
[TBL] [Abstract][Full Text] [Related]
18. Socioeconomic and Demographic Characteristics of US Adults Who Purchase Prescription Drugs From Other Countries.
Hong YR; Hincapie-Castillo JM; Xie Z; Segal R; Mainous AG
JAMA Netw Open; 2020 Jun; 3(6):e208968. PubMed ID: 32579194
[TBL] [Abstract][Full Text] [Related]
19. Treatment Patterns and Relapses Among Newly Treated Multiple Sclerosis Patients From a Retrospective Claims Analysis.
Kantor D; Mehta R; Pelletier C; Tian M; Noxon V; Johnson BH; Bonafede M
Clin Ther; 2020 Nov; 42(11):2136-2147.e3. PubMed ID: 33160682
[TBL] [Abstract][Full Text] [Related]
20. Patterns of Dementia Treatment and Frank Prescribing Errors in Older Adults With Parkinson Disease.
Mantri S; Fullard M; Gray SL; Weintraub D; Hubbard RA; Hennessy S; Willis AW
JAMA Neurol; 2019 Jan; 76(1):41-49. PubMed ID: 30285047
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
